Vertex Pharmaceuticals Inc (VRTX)
422.78
+3.79
(+0.90%)
USD |
NASDAQ |
May 10, 16:00
422.82
+0.04
(+0.01%)
After-Hours: 20:00
Vertex Pharmaceuticals Cash from Financing (Quarterly): -357.50M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -357.50M |
December 31, 2023 | -119.80M |
September 30, 2023 | -165.00M |
June 30, 2023 | 17.30M |
March 31, 2023 | -294.70M |
December 31, 2022 | 40.20M |
September 30, 2022 | -60.20M |
June 30, 2022 | 47.70M |
March 31, 2022 | -95.40M |
December 31, 2021 | -336.20M |
September 30, 2021 | -656.70M |
June 30, 2021 | 33.60M |
March 31, 2021 | -518.70M |
December 31, 2020 | -125.21M |
September 30, 2020 | -140.68M |
June 30, 2020 | 120.02M |
March 31, 2020 | -359.43M |
December 31, 2019 | 161.45M |
September 30, 2019 | 20.36M |
June 30, 2019 | -13.02M |
March 31, 2019 | -41.99M |
December 31, 2018 | -101.05M |
September 30, 2018 | 2.079M |
June 30, 2018 | -51.21M |
March 31, 2018 | 78.96M |
Date | Value |
---|---|
December 31, 2017 | 73.23M |
September 30, 2017 | 152.70M |
June 30, 2017 | 132.03M |
March 31, 2017 | -289.56M |
December 31, 2016 | 93.76M |
September 30, 2016 | 13.55M |
June 30, 2016 | 21.25M |
March 31, 2016 | 4.702M |
December 31, 2015 | 52.64M |
September 30, 2015 | 49.67M |
June 30, 2015 | 36.20M |
March 31, 2015 | 50.41M |
December 31, 2014 | 108.18M |
September 30, 2014 | 357.23M |
June 30, 2014 | 33.40M |
March 31, 2014 | 50.42M |
December 31, 2013 | 84.05M |
September 30, 2013 | 13.01M |
June 30, 2013 | 157.49M |
March 31, 2013 | -6.135M |
December 31, 2012 | 4.837M |
September 30, 2012 | 8.15M |
June 30, 2012 | 137.69M |
March 31, 2012 | 21.52M |
December 31, 2011 | -182.98M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-656.70M
Minimum
Sep 2021
161.45M
Maximum
Dec 2019
-140.10M
Average
-107.60M
Median
Cash from Financing (Quarterly) Benchmarks
Amgen Inc | -1.708B |
Eli Lilly and Co | -311.30M |
Regeneron Pharmaceuticals Inc | 47.10M |
Alpine Immune Sciences Inc | 156.61M |
Editas Medicine Inc | 0.192M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | 1.307B |
Cash from Investing (Quarterly) | -2.136B |
Free Cash Flow | 3.479B |
Free Cash Flow Per Share (Quarterly) | 4.053 |
Free Cash Flow to Equity (Quarterly) | 1.058B |
Free Cash Flow to Firm (Quarterly) | 1.058B |
Free Cash Flow Yield | 3.16% |